Human Immunodeficiency Virus Type 1 in the Semen of Men Receiving Highly Active Antiretroviral Therapy
- 17 December 1998
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 339 (25) , 1803-1809
- https://doi.org/10.1056/nejm199812173392502
Abstract
Highly active antiretroviral therapy can effectively decrease the levels of human immunodeficiency virus type 1 (HIV-1) virions in peripheral plasma and seminal fluid of infected men. Whether the genital tract of HIV-1–infected men who are receiving highly active antiretroviral therapy and who have no detectable virus in the peripheral plasma harbors replication-competent virus is not known.Keywords
This publication has 43 references indexed in Scilit:
- Quantification of HIV in semenAIDS, 1997
- The epidemiology of HIV-associated Kaposiʼs sarcomaAIDS, 1996
- Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8 + T CellsScience, 1995
- Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission.Journal of Clinical Investigation, 1994
- Reverse Transcription Takes Place within Extracellular HIV-1 Virions: Potential Biological SignificanceAIDS Research and Human Retroviruses, 1993
- Detection of Human Immunodeficiency Virus Type 1 in Semen: Effects of Disease Stage and Nucleoside TherapyThe Journal of Infectious Diseases, 1993
- Effects of disease stage and zidovudine therapy on the detection of human immunodeficiency virus type 1 in semenJAMA, 1992
- Recovery of Human Immunodeficiency Virus Type 1 from Semen: Minimal Impact of Stage of Infection and Current Antiviral ChemotherapyThe Journal of Infectious Diseases, 1991
- Infection of the Retina by Human Immunodeficiency Virus Type INew England Journal of Medicine, 1987
- Pathogenesis of Infection with Human Immunodeficiency VirusNew England Journal of Medicine, 1987